Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Transthyretin Amyloidosis Treatment Market Growth in 2025?

The market for transthyretin amyloidosis treatment has seen robust growth in recent times. It is projected to expand from a value of $5.52 billion in 2024 to $5.95 billion in 2025, with a compound annual growth rate (CAGR) of 7.8%. Factors contributing to growth during the historical period include heightened awareness of the disease, progression in diagnostic instruments, the evolution of drug development and validation, patient backing and advocacy, and cooperative efforts in research.

What Is the Forecast for the Transthyretin Amyloidosis Treatment Market Size Through 2029?

The market size for the treatment of transthyretin amyloidosis is anticipated to expand robustly in the forthcoming years. The projected growth will reach $8.04 billion by 2029, with a CAGR of 7.8%. This expected surge within the forecast period can be credited to aspects such as the widened therapeutic pipeline, increased genetic screenings, global initiatives for rare disease awareness, the application of personalized medical strategies, and better avenues to access treatment. Noteworthy trends during the forecast period involve the advent of combination therapies, creation of strategic alliances for drug development, an emphasis on targeting peripheral and cardiac complications, the launch of patient education programs, and the inclusion of real-world evidence in treatment guidelines.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13129&type=smp

What are the Key Market Players in Transthyretin Amyloidosis Treatment Market and How They’re Evolving?

Major companies operating in the transthyretin amyloidosis treatment market report are Pfizer Inc., Abbvie Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, GSK PLC, Novo Nordisk A/S, Merck & Co. Inc., Astellas Pharma Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics, Ionis Pharmaceuticals, Prothena Corporation PLC, BridgeBio Pharma Inc., Sorrento Therapeutics Inc., Intellia Therapeutics, Akcea Therapeutics Inc., Eidos Therapeutics Inc., Acrotech Biopharma Inc., Spectrum Pharmaceuticals Inc., Neurimmune AG, BELLUS Health Inc., Corino Therapeutics Inc., Celgene Corp, SOM Innovation Biotech S.A

What Are the Primary Growth Drivers in the Transthyretin Amyloidosis Treatment Market?

The anticipated surge in the transthyretin amyloidosis treatment market is largely due to the increasing funds being invested in research and development. These investments are directed towards broadening our scientific understanding, forging new technologies, devising innovative products, and upgrading current methodologies. Such financial support facilitates the conception and cultivation of avant-garde treatment methods for transthyretin amyloidosis. These include new-age medicinal drugs, gene interventions, and precision-oriented medicinal strategies, providing patients with focused and efficient treatment alternatives. As a case in point, Alnylam Pharmaceuticals, an American biopharmaceutical firm working on Vutrisiran, meant for ATTR amyloidosis treatment, raised its R&D investment to $883,015 in 2022, from $792,156 in 2021, indicating a growth rate of 11.49%. Hence, an upswing in research and development funding will fuel the growth of the transthyretin amyloidosis treatment market. The growth of the transthyretin amyloidosis treatment market is likely to be amplified by the ever-growing aged population demographic. The phrase “aging population” denotes a demographic transformation where the average age of a population rises due to falling birth rates and extended lifespan. Ageing is a critical risk factor for transthyretin amyloidosis (ATTR), and with an aging population, there’s a higher occurrence of Transthyretin Amyloidosis cases. This results in an expanding pool of patients necessitating treatment. For instance, the World Health Organization, a Switzerland-located agency of the United Nations tasked with global public health matters, disclosed in October 2022 that all counties worldwide are seeing a rise in the number and proportion of aged individuals. By 2030, it’s predicted that one out of every six people globally will be aged 60 or above. Consequently, the increasing aged population demographic is bolstering the transthyretin amyloidosis treatment market’s expansion.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13129&type=smp

What Are the Leading Segments in the Global Transthyretin Amyloidosis Treatment Industry?

The transthyretin amyloidosis treatment market covered in this report is segmented –

1) By Type: Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

2) By Drug: Tafamidis, Patisiran, Inotersen, Other Drugs

3) By Therapy: Targeted Therapy, Supportive Therapy, Pipeline Therapy

4) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN): Early-Stage ATTR-PN, Advanced-Stage ATTR-PN

2) By Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM): Mild ATTR-CM, Moderate ATTR-CM, Severe ATTR-CM

What Are the Key Market Trends in the Transthyretin Amyloidosis Treatment Industry?

Transthyretin amyloidosis treatment market’s principal companies are concentrating on creating unique and groundbreaking therapies, including orphan drugs, to increase patient outcomes and broaden the treatment possibilities. Eplontersen, an orphan drug developed specifically for the transthyretin amyloidosis condition, often gains regulatory advantages to aid its progress. For example, Canada’s Ionis Pharmaceuticals Inc., a biotechnology research firm, was granted The Food and Drug Administration (FDA) approval for a new drug application for Eplontersen in March 2023. This experimental orphan drug is designed to treat familial transthyretin-mediated amyloid, which leads to progressive polyneuropathy. Eplontersen is a medicinal compound designed to reduce the production of transthyretin (TTR) protein to help both inherited and non-hereditary types of ATTR amyloidosis (amyloid transthyretin amyloidosis). Eplontersen was given orphan drug status by the FDA in 2022.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/transthyretin-amyloidosis-treatment-global-market-report

What Is the Regional Outlook for the Transthyretin Amyloidosis Treatment Market?

North America was the largest region in the transthyretin amyloidosis treatment market in 2024. The regions covered in the transthyretin amyloidosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13129

This Report Delivers Insight On:

1. How big is the transthyretin amyloidosis treatment market, and how is it changing globally?

2. Who are the major companies in the transthyretin amyloidosis treatment market, and how are they performing?

3. What are the key opportunities and risks in the transthyretin amyloidosis treatment market right now?

4. Which products or customer segments are growing the most in the transthyretin amyloidosis treatment market?

5. What factors are helping or slowing down the growth of the transthyretin amyloidosis treatment market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model